OnKure Therapeutics (NASDAQ:OKUR) Now Covered by Leerink Partners

Leerink Partners initiated coverage on shares of OnKure Therapeutics (NASDAQ:OKUR) in a report issued on Thursday morning, MarketBeat reports. The firm issued an outperform rating and a $33.00 target price on the stock.

OKUR has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of OnKure Therapeutics in a research report on Friday, November 8th. Lifesci Capital upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, October 10th. Finally, Oppenheimer started coverage on shares of OnKure Therapeutics in a research note on Thursday, October 10th. They issued an “outperform” rating and a $35.00 price objective on the stock. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $36.00.

OnKure Therapeutics Stock Performance

Shares of NASDAQ OKUR opened at $14.20 on Thursday. OnKure Therapeutics has a 52-week low of $9.80 and a 52-week high of $77.60. The company has a 50 day simple moving average of $16.83. The firm has a market cap of $47.47 million, a PE ratio of -1.16 and a beta of 0.14.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.13). On average, analysts expect that OnKure Therapeutics will post -4.21 EPS for the current year.

About OnKure Therapeutics

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.